Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors-Reference-Cited by-同舟云学术

Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors

Published:2016-05-23 Issue:7 Volume:6 Page:740-753
ISSN:2159-8274
Container-title:Cancer Discovery
language:en
Short-container-title:Cancer Discov

Author:

Patnaik Amita,Rosen Lee S.,Tolaney Sara M.,Tolcher Anthony W.,Goldman Jonathan W.,Gandhi Leena,Papadopoulos Kyriakos P.,Beeram Muralidhar,Rasco Drew W.,Hilton John F.,Nasir Aejaz,Beckmann Richard P.,Schade Andrew E.,Fulford Angie D.,Nguyen Tuan S.,Martinez Ricardo,Kulanthaivel Palaniappan,Li Lily Q.,Frenzel Martin,Cronier Damien M.,Chan Edward M.,Flaherty Keith T.,Wen Patrick Y.,Shapiro Geoffrey I.

Publisher

American Association for Cancer Research (AACR)

Subject

Oncology

Cited by 563 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and Safety of Abemaciclib in Combination With Endocrine Therapy for HR+/HER2− Advanced or Metastatic Breast Cancer;American Journal of Clinical Oncology;2024-09-09

2. Challenges of Renal Function Assessment in Breast Cancer Patients Treated With Abemaciclib: A Case Report;Cureus;2024-08-25

3. Next-generation sequencing-based evaluation of the actionable landscape of genomic alterations in solid tumors: the “MOZART” prospective observational study;The Oncologist;2024-08-23

4. Slower CDK4 and faster CDK2 activation in the cell cycle;Structure;2024-08

5. Establishment of a trastuzumab-resistant extramammary Paget disease model: loss of PTEN as a potential mechanism;British Journal of Cancer;2024-07-10